Psilocybin (P-TRD) study
You are here:
The Safety and Efficacy of Psilocybin in Participants With Treatment Resistant Depression (P-TRD)
This is a randomised controlled phase IIb study of psilocybin therapy in patients with treatment-resistant depression in 21 sites across Europe and North America.
The aim of this trial is to determine whether psilocybin delivered with psychological support and medical supervision is a safe and effective treatment for people with difficult to treat depression. To determine this, the trial collects detailed data on adverse events as well as comparing participant’s ratings of their depression symptoms before and after treatment. The trial is being funded by a life sciences company, COMPASS Pathways Ltd. that received US Food and Drug Administration (FDA) “Breakthrough Therapy” designation in 2018 for their program of psilocybin therapy in treatment-resistant depression.
The trial in our site is approved by the German Federal Institute for Drugs and Medical Devices (BfArM) and the Ethics Committee of LAGeSo (Landesamt für Gesundheit und Soziales Berlin)
For more information on this trial you can refer to https://compasspathways.com/our-research/psilocybin-therapy/our-clinical-trials/treatment-resistant-depression/
or contact us at psilocybin(at)charite.de.